Soligenix, Inc. (SNGX) Q3 Net Loss Falls To $1.1M; Cash Is $9.0M

Soligenix reported no revenue for Q3 2026, with a net loss of $1.1M, or $0.05 per share, down from $2.5M a year earlier. The company had $9.0M in cash at the end of the quarter. The results follow the termination of the FLASH2 trial and reduced development activities for HyBryte.

Original reporting
Published Nov 6, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Soligenix, Inc. (SNGX) Q3 Net Loss Falls To $1.1M; Cash Is $9.0M — source image
Decision brief

The 30-second read

$SNGXBearishLow
01

Why it matters

The Q3 loss highlights execution risk and may trigger short‑term price decline.

02

Market read

Quarterly earnings update for a micro‑cap biotech, likely prompting modest price movement.

03

What to watch

Potential upcoming partnership or licensing deals could offset the loss.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Soligenix provides therapies for rare diseases; recent trial terminations have reduced its pipeline.

Company-level read

Ticker impact

$SNGXBearishHigh confidence
Context

Q3 2026 net loss reported at $1.1M versus $2.5M a year earlier, with cash of $9.0M.

Expected impact

downward pressure as investors price in higher loss and limited cash runway

Evidence & confidence

Quarterly loss more than doubles YoY; no revenue and cash balance modest, likely prompting sell‑side activity.

Market effects

Biotech small‑cap sector may see broader risk‑off sentiment due to weaker earnings.

Limited to US OTC/ Nasdaq micro‑cap investors.

Minimal global impact.

Counterpoint

Long‑term investors may view the cash position as sufficient for upcoming trial milestones.

Key entities

  • Soligenix, Inc.

    Biotech firm developing treatments for rare diseases.

Related articles

$SNGXMedAI 8/10

Soligenix culls topical lymphoma asset after Phase III miss

Soligenix terminated the Phase III FLASH2 trial for its topical CTCL therapy HyBryte (SGX301/synthetic hypericin sodium) after interim analysis indicated it was unlikely to meet primary goals. The company will shift focus to dusquetide for Behçet’s disease and pursue commercial opportunities for its ThermoVax vaccine platform. The article also notes CTCL drug approvals and sales figures.

$SNGXMed

SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Soligenix (Nasdaq: SNGX) reported no revenue for the quarter ended June 30, 2026. Net loss was $2.0 million, or ($0.12) per share, versus $2.7 million, or ($0.82) per share, a year earlier. The company said it discontinued its HyBryte (synthetic hypericin) Phase 3 FLASH2 program after a futility recommendation. Cash was about $9.8 million as of June 30, 2026.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In